A development of novel vectors and an establishment of a new generation of hepatic gene therapy for congenital metabolic diseases

新型载体的开发及新一代先天性代谢性疾病肝脏基因治疗的建立

• 批准号: 12670798
• 负责人: KOSAI Ken-ichiro
• 金额: $ 2.18万
• 依托单位: Gifu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670798/
• 关键词: Gene therapy; Congenital metabolic diseases; Adenovirus; Retrovirus; Liver; Chimeric virus; Gutted adenovirus; Gene transduction; 血友病; 遺伝子導入; ガットレス

<Aim>Gene therapy may be the most promising therapeutics for many of congenital metabolic diseases. The largest obstacle of its clinical application is currently no available vector that is capable of in vivo high gene transduction efficiency and the sequential long-term gene expression, both of which are necessary for treating congenital metabolic diseases. The aim of the present study is to develop adeno-retro-chimeric vector and less immunogenic gutted adenoviral vector and to establish novel hepatic gene therapy using them.<Results>1. We developed adeno-retro-chimeric vector and studied their function.2. We developed gutted adenoviral vector and studied their function.3. We studied mechanisms of hepatic regeneration and hepatocyte death, especially biological roles and therapeutic potentials of hepatocyte growth fadctor and heparin-binding EGF.4. We developed some novel gene therapy for inveterate diseases using adenoviral vector.<Future plan>We will further study the therapeutic potential and adverse effects of these vectors and hepatic gene therapy in various animal models.

基因治疗可能是许多先天性代谢性疾病最有前途的治疗方法。其临床应用的最大障碍是目前没有能够在体内实现高基因转导效率和序列性基因长期表达的载体，而这两者是治疗先天性代谢性疾病所必需的。本研究的目的是建立腺逆转录嵌合载体和免疫原性较低的内脏腺病毒载体，并利用它们建立新的肝脏基因治疗方法。我们构建了腺逆转录嵌合载体，并对其功能进行了研究。我们制备了腺病毒内脏载体，并对其功能进行了研究。我们研究了肝再生和肝细胞死亡的机制，特别是肝细胞生长因子和肝素结合egf的生物学作用和治疗潜力。我们利用腺病毒载体开发了一些新的治疗顽固性疾病的基因疗法。<未来计划>我们将在各种动物模型上进一步研究这些载体和肝脏基因治疗的治疗潜力和不良反应。

项目成果

小財健一郎 他、: "コンビネーション癌遺伝子治療と新しい遺伝子治療開発の試み"コンビネーション癌遺伝子治療と新しい遺伝子治療開発の試み. (印刷中). (2000)

Kenichiro Kozai 等人：“组合癌症基因疗法和开发新基因疗法的尝试”组合癌症基因疗法和开发新基因疗法的尝试（2000 年出版）。

Miyado K, et al.: "Requirement of CD9 on egg plasma membrane for fertilization"Science. 287. 321-324 (2000)

Miyado K 等人：“受精卵质膜上 CD9 的要求”科学。

小財健一郎 他、: "HGF(肝細胞増殖因子)による劇症肝炎の治療"小児科. 41(3). 381-390 (2000)

Kenichiro Kozai 等：“用 HGF（肝细胞生长因子）治疗暴发性肝炎”《儿科学》41(3) 381-390 (2000)。

Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A.: "Induction of the cytokine signal regulator, SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis"The Jou

Shouda T、Yoshida T、Hanada T、Wakioka T、Oishi M、Miyoshi K、Komiya S、Kosai K、Hanakawa Y、Hashimoto K、Nagata K、Yoshimura A.：“细胞因子信号调节剂 SOCS3/CIS3 的诱导

寺崎泰宏 他、: "胃癌肝転移に対する臨床応用を目指した自殺遺伝子治療の研究"Biotherapy. 14(5). 498-501 (2000)

Yasuhiro Terasaki 等：“针对胃癌肝转移的临床应用的自杀基因治疗的研究”Biotherapy 14(5)。